LibraryReviewed entriesUpdated 2 Nov 2026
The library
One entry per compound. Each gives its identity, what the published studies measured and on which animals, every human report on record, and its legal and anti-doping status. Entries are numbered, dated and signed, and every change is logged.
31Entries at launch
6Shelves
31Published so far
WeeklyNew entries
All entries, A–Z
31 of 31 entries| No. | Compound | Shelf | Avg mass | Status |
|---|---|---|---|---|
| A | ||||
| 0019 | AOD-9604Growth hormone fragment 176–191 | Metabolic | 1815.1 g/mol | Published |
| B | ||||
| 0025 | Bacteriostatic waterSolvent, store and methods only | Methods | — | Published |
| 0001 | BPC-157Pentadecapeptide from a gastric juice protein | Tissue repair | 1419.5 g/mol | Published |
| C | ||||
| 0020 | CagrilintideAmylin analogue | Metabolic | 4409.1 g/mol | Published |
| 0010 | CJC-1295GHRH analogue | Growth hormone axis | 3647.3 g/mol | Published |
| D | ||||
| 0023 | DSIPDelta sleep-inducing peptide | Nootropic | 848.8 g/mol | Published |
| E | ||||
| 0015 | EpitalonTetrapeptide | Growth hormone axis | 390.4 g/mol | Published |
| G | ||||
| 0003 | GHK-CuCopper-binding tripeptide | Skin and copper | 401.9 g/mol | Published |
| 0021 | GLOWBlend: BPC-157 10 mg + TB-500 5 mg. In store | Tissue repair | 2309 g/mol | Published |
| I | ||||
| 0009 | IpamorelinPentapeptide secretagogue | Growth hormone axis | 711.9 g/mol | Published |
| K | ||||
| 0024 | Kisspeptin-10Decapeptide | Growth hormone axis | 1302.4 g/mol | Published |
| 0022 | KLOWBlend: KPV, GHK-Cu, BPC-157, TB-500 | Skin and copper | 3053 g/mol | Published |
| 0006 | KPVTripeptide from alpha-MSH | Tissue repair | 342.4 g/mol | Published |
| L | ||||
| 0031 | LL-37Human cathelicidin peptide | Tissue repair | 4493.3 g/mol | Published |
| M | ||||
| 0028 | MazdutideGLP-1 / glucagon dual agonist | Metabolic | 4563.1 g/mol | Published |
| 0026 | Melanotan IICyclic alpha-MSH analogue. In store | Skin and copper | 1024.2 g/mol | Published |
| 0013 | MOTS-cMitochondrial-derived peptide | Mitochondrial | 2174.6 g/mol | Published |
| N | ||||
| 0014 | NAD+Coenzyme | Mitochondrial | 663.4 g/mol | Published |
| O | ||||
| 0029 | OrforglipronOral GLP-1 agonist, not a peptide | Metabolic | 883.0 g/mol | Published |
| P | ||||
| 0018 | PT-141Melanocortin agonist | Metabolic | 1025.2 g/mol | Published |
| R | ||||
| 0005 | RetatrutideTriple agonist, GLP-1 / GIP / glucagon. In store as GLP-3 | Metabolic | 4731 g/mol | Published |
| S | ||||
| 0011 | SelankHeptapeptide, tuftsin analogue | Nootropic | 751.9 g/mol | Published |
| 0007 | SemaglutideGLP-1 analogue | Metabolic | 4113.6 g/mol | Published |
| 0012 | SemaxHeptapeptide, ACTH fragment analogue | Nootropic | 813.9 g/mol | Published |
| 0016 | SermorelinGHRH 1–29 | Growth hormone axis | 3357.9 g/mol | Published |
| 0030 | SS-31Mitochondria-targeted tetrapeptide | Mitochondrial | 639.8 g/mol | Published |
| 0027 | SurvodutideGlucagon / GLP-1 dual agonist | Metabolic | 4231.7 g/mol | Published |
| T | ||||
| 0002 | TB-500Seven-residue fragment of thymosin beta-4 | Tissue repair | 889.0 g/mol | Published |
| 0004 | TesamorelinGHRH analogue | Growth hormone axis | 5135.9 g/mol | Published |
| 0017 | Thymosin alpha-128-residue thymic peptide | Tissue repair | 3108.3 g/mol | Published |
| 0008 | TirzepatideDual agonist, GLP-1 / GIP | Metabolic | 4813.5 g/mol | Published |
Compare
Comparisons
Shelves
Browse by shelf
Shelf 01Tissue repairPeptides studied in wound, tendon, gut and vessel models.BPC-157 · GLOW · TB-500 · KPV · Thymosin alpha-1
Shelf 02MetabolicIncretin and amylin analogues studied for appetite and glucose.Semaglutide · Tirzepatide · Retatrutide · Cagrilintide · AOD-9604
Shelf 03Growth hormone axisReleasing hormones and secretagogues.Tesamorelin · Ipamorelin · CJC-1295 · Sermorelin · Kisspeptin-10
Shelf 04Skin and copperCopper peptides and the blends built on them.GHK-Cu · Melanotan II · KLOW
Shelf 05NootropicShort peptides studied in the nervous system.Selank · Semax · DSIP
Shelf 06MitochondrialPeptides and cofactors studied in energy metabolism.MOTS-c · NAD+ · SS-31
About
How entries are written
Every entry is written from the primary papers, not from other websites. We say what was measured, in which model, by whom, and we separate animal work from human work. We do not describe effects in people, and we do not give instructions for use. A named scientific editor signs each revision, and the methods pages explain how our lots are tested. Read the editorial policy.